Search
caplacizumab-yhdp (Cablivi)
Indications:
- thrombotic thrombocytopenic purpura
Dosage:
- injection 11 mg
Mechanism of action:
- prevents formation of platelet aggregates & microvascular thrombosis by inhibiting von Willebrand factor
- for lasting remission in acquired TTP, may be necessary to restore normal levels of ADAMTS13, (vWF-cleaving protease)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Peyvandi F et al.
Caplacizumab for acquired thrombotic thrombocytopenic purpura.
N Engl J Med 2016 Feb 11; 374:511.
PMID: 26863353
- Veyradier A.
Von Willebrand Factor - A new target for TTP treatment?
N Engl J Med 2016 Feb 11; 374:583.
PMID: 26863360
- RxNorm